Xolair Omalizumab - 150mg Vial for Subcutaneous Use

Object Details

Genentech, Inc.

Novartis Vaccines and Diagnostics Limited

Description (Brief): (From box); For subcutaneous use; (From insert); Xolair is indicated for:; -Moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids.; Important Limitations of use:; -Not indicated for other allergic conditions; -Not indicated for acute bronchospasm or status asthmaticus; -Not indicated for pediatric patients less than 12 years of age
Location: Currently not on view

Physical Description: glass (overall material); metal (overall material); plastic (overall material); paper (overall material); cardboard (overall material); Omalizumab, 150mg (overall ingredient)
Measurements: overall: 1 in x 2 1/8 in x 3 3/8 in; 2.54 cm x 5.3975 cm x 8.5725 cm; bottle of sterile water for injection: 2 3/16 in x 1 in; 5.55625 cm x 2.54 cm; 10ml syringe: 1 7/8 in x 8 1/4 in x 3/4 in; 4.7625 cm x 20.955 cm x 1.905 cm; alcohol wipe: 2 in x 2 in; 5.08 cm x 5.08 cm; overall: 3 3/8 in x 2 in x 1 in; 8.5725 cm x 5.08 cm x 2.54 cm

See more items in: Medicine and Science: Medicine; Health & Medicine; The Antibody Initiative; Antibody Initiative: Monoclonal Antibodies

National Museum of American History

GUID (Link to Original Record): https://n2t.net/ark:/65665/ng49ca746ad-e4b7-704b-e053-15f76fa0b4fa